NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive announcements, the company's share price fell by 4.62% over the past month. This decline aligns with broader market trends, including the sharp downturn in major indices triggered by renewed tariff tensions and a weak jobs report. In contrast, Lilly's progress in diabetes and Alzheimer's treatments...